Literature DB >> 22471285

Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells.

A Iwata1, R Shirai, H Ishii, H Kushima, S Otani, K Hashinaga, K Umeki, K Kishi, I Tokimatsu, K Hiramatsu, J Kadota.   

Abstract

Statins are 3-hydroxy-3-methylglutaryl-co-enzyme A reductase inhibitors of cholesterol biosynthesis, and have been reported to exert pleiotropic effects on cellular signalling and cellular functions involved in inflammation. Recent reports have demonstrated that previous statin therapy reduced the risk of pneumonia or increased survival in patients with community-acquired pneumonia. However, the precise mechanisms responsible for these effects are unclear. In the present study, we examined the effects of statins on cytokine production from lipopolysaccharide (LPS)-stimulated human bronchial epithelial cells (BEAS-2B). Interleukin (IL)-6 and IL-8 mRNA expression and protein secretion in LPS-stimulated cells were inhibited significantly by the lipophilic statin pitavastatin and the hydrophilic statin pravastatin. As these inhibitory effects of statin were negated by adding mevalonate, the anti-inflammatory effects of statins appear to be exerted via the mevalonic cascade. In addition, the activation levels of Ras homologue gene family A (RhoA) in BEAS-2B cells cultured with pitavastatin were significantly lower than those without the statin. These results suggest that statins have anti-inflammatory effects by reducing cytokine production through inhibition of the mevalonic cascade followed by RhoA activation in the lung.
© 2012 The Authors;Clinical and Experimental Immunology © 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22471285      PMCID: PMC3390525          DOI: 10.1111/j.1365-2249.2012.04564.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors.

Authors:  P A Kiener; P M Davis; J L Murray; S Youssef; B M Rankin; M Kowala
Journal:  Int Immunopharmacol       Date:  2001-01       Impact factor: 4.932

Review 2.  Antiinflammatory and immunomodulatory properties of statins.

Authors:  Ora Shovman; Yair Levy; Boris Gilburd; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 3.  Rho family members: activators of MAP kinase cascades.

Authors:  A B Vojtek; J A Cooper
Journal:  Cell       Date:  1995-08-25       Impact factor: 41.582

Review 4.  Regulation of HMG-CoA reductase.

Authors:  V W Rodwell; J L Nordstrom; J J Mitschelen
Journal:  Adv Lipid Res       Date:  1976

5.  Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients.

Authors:  Elia Ascer; Marcelo C Bertolami; Margareth L Venturinelli; Valéria Buccheri; Juliana Souza; José C Nicolau; José Antônio F Ramires; Carlos V Serrano
Journal:  Atherosclerosis       Date:  2004-11       Impact factor: 5.162

6.  Potentiation by granulocyte macrophage colony-stimulating factor of lipopolysaccharide toxicity in mice.

Authors:  G Tiegs; J Barsig; B Matiba; S Uhlig; A Wendel
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

7.  Prior statin therapy is associated with a decreased rate of severe sepsis.

Authors:  Yaniv Almog; Alexander Shefer; Victor Novack; Nimrod Maimon; Leonid Barski; Miruna Eizinger; Michael Friger; Lior Zeller; Abraham Danon
Journal:  Circulation       Date:  2004-08-02       Impact factor: 29.690

8.  Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide.

Authors:  Jian-Jun Li; Xue-Jun Chen
Journal:  Coron Artery Dis       Date:  2003-06       Impact factor: 1.439

9.  Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease.

Authors:  Hannes Franz Alber; Matthias Frick; Alois Süssenbacher; Jakob Dörler; Wolfgang Dichtl; Eva-Maria Stocker; Otmar Pachinger; Franz Weidinger
Journal:  Wien Med Wochenschr       Date:  2007-02

Review 10.  Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension.

Authors:  Claudio Borghi; Ada Dormi; Maddalena Veronesi; Vincenzo Immordino; Ettore Ambrosioni
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Jul-Aug       Impact factor: 3.738

View more
  26 in total

1.  Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy.

Authors:  Amir A Zeki
Journal:  Eur Respir J       Date:  2014-04       Impact factor: 16.671

2.  Statins and asthma: where we stand, and the next critical steps in research.

Authors:  Amir A Zeki
Journal:  Curr Med Res Opin       Date:  2014-01-30       Impact factor: 2.580

3.  Roles of the Mevalonate Pathway and Cholesterol Trafficking in Pulmonary Host Defense.

Authors:  Kristin A Gabor; Michael B Fessler
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

4.  Cholesterol is required for stability and infectivity of influenza A and respiratory syncytial viruses.

Authors:  Shringkhala Bajimaya; Tünde Frankl; Tsuyoshi Hayashi; Toru Takimoto
Journal:  Virology       Date:  2017-07-25       Impact factor: 3.616

Review 5.  Innovations in asthma therapy: is there a role for inhaled statins?

Authors:  Amir A Zeki; Mona Elbadawi-Sidhu
Journal:  Expert Rev Respir Med       Date:  2018-05-03       Impact factor: 3.772

Review 6.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

7.  HMG-CoA Reductase Inhibitors for Prevention and Treatment of Severe Sepsis.

Authors:  Joel D Mermis; Steven Q Simpson
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

8.  Novel applications of statins for bone regeneration.

Authors:  Sarita R Shah; Caroline A Werlang; F Kurtis Kasper; Antonios G Mikos
Journal:  Natl Sci Rev       Date:  2014-08-16       Impact factor: 17.275

9.  Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis.

Authors:  Mozaffarul Islam; Smita Sharma; Bhavna Kumar; Theodoros N Teknos
Journal:  Oral Oncol       Date:  2013-05-04       Impact factor: 5.337

10.  Statin therapy in patients with community-acquired pneumonia.

Authors:  Frances S Grudzinska; Davinder Ps Dosanjh; Dhruv Parekh; Rachel Ca Dancer; Jaimin Patel; Peter Nightingale; Georgia M Walton; Elizabeth Sapey; David R Thickett
Journal:  Clin Med (Lond)       Date:  2017-10       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.